In this study, we used MethyLight to detect the methylation status of the IL-6 promoter in patients with HBV-associated HCC, chronic hepatitis B (CHB) and healthy controls (HCs) as well as analyze the correlation between the IL-6 promoter methylation level and other clinicopathological characteristics. Here, IL6 is linked to hepatocellular carcinoma.